4yr
The Effect of Body Mass Index on Treatment Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Platinum-Based Therapy 1.
Source : https://oncologynation.com/journal/61967
Oncology Nation is the leading online medical community exclusively for Oncologists and Hematologists enabling specialized consultation, communication, and information exchange within a private and secure platform.
A high BMI prior to therapy in patients with NSCLC treated with platinum-based ChT in the first-line setting was associated with more favorable PFS and OS.
• Source: Nutrition and Cancer
• Conclusion/Relevance: “A high BMI prior to therapy in patients with NSCLC treated with platinum-based ChT [chemotherapy] in the first-line setting was associated with more favorable PFS and OS.”
• In the current study, researchers retrospectively investigated the effect of BMI on treatment outcomes/adverse effects in 233 patients with metastatic non-small cell lung cancer (NSCLC) administered 1L platinum-based chemotherapy.
• The median PFS was 7 months in those with a BMI ≥ 25 kg/m2 vs 5.0 months in those with a BMI < 25 kg/m2 (p = ); median OS durations were 12 vs 9 months (p = 0.003), respectively. ECOG PS 2, grade III histology, and brain/bone metastasis negatively correlated with OS, whereas BMI ≥ 25 kg/m2 was positive correlated with OS.
• Experts have previously suggested that a decreased BMI may enhance the sensitivity of DNA to numerous chemical carcinogens in healthy populations, with higher body weight linked to a decline in chromosomal damage. Additionally, adipose tissue could be important in maintaining T cell memory to maintain normal immune functions. Cancer-related cachexia also decreases BMI.
• The authors noted that BMI is a factor associated with immuno-nutritional status and could reflect the nutritional status of cancer patients. Some research has focused on the prognostic effect of BMI on postoperative outcomes in NSCLC patients and shown that low BMI was linked to worse clinical outcomes after surgery.
• “Unlike the other studies in the literature, we selected more homogenous groups of patients who received platinum-based ChT in the first-line setting,” the authors wrote. “In addition, we evaluated the relationship between BMI and response to treatment, treatment change, and side-effect profile. However, the study had some limitations; it was a retrospective and single-centered study, with a relatively small number of cases. In addition, we could not explain by which mechanism the low BMI (<25 kg/m2) adversely affected the clinical outcomes in patients with metastatic NSCLC.”